 MENLO PARK, Calif., Nov. 23, 2020 GLOBE NEWSWIRE -- Corcept Therapeutics Incorporated NASDAQ: CORT, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the companys Board of Directors. 